Loading
Latest filing published 30 Nov 2018 for Oncolytics Biotech Inc..
No signal scores available.
John Mark Lievonen discloses dealings in Oncolytics Biotech Inc. to SEDI. Over a trading history stretching from 22 May 2018 to 28 November 2018, the count stands at 2 filings.
Not one of the filings records a straightforward purchase or sale on the market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The latest filing, published on 30 November 2018, reports a transaction in Oncolytics Biotech Inc. These figures are compiled from regulatory filings published by SEDI. They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations